Reply to 'Therapeutic drug monitoring for isoniazid and rifampicin exposure'

Int J Tuberc Lung Dis. 2024 Mar 1;28(3):169-170. doi: 10.5588/ijtld.24.0022.
No abstract available

MeSH terms

  • Antitubercular Agents / adverse effects
  • Drug Monitoring
  • Humans
  • Isoniazid* / adverse effects
  • Mycobacterium tuberculosis*
  • Rifampin / adverse effects

Substances

  • Isoniazid
  • Rifampin
  • Antitubercular Agents